SHTDF (Sinopharm Group Co) EBIT: $2,405 Mil (TTM As of Dec. 2025)


SHTDF Sinopharm Group Co Ltd SHTDF
78 GF Score
Price $2.29
GF Value $2.99
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is Sinopharm Group Co EBIT?

Sinopharm Group Co SHTDF -2.67% 78 EBIT is $2,405 Mil as of Dec. 2025. GuruFocus rates SHTDF with a GF Score™ of 78/100 and a GF Value™ of $2.99 (Modestly Undervalued). The stock has 4 warning signs investors should review.

Sinopharm Group Co's earnings before interest and taxes (EBIT) for the six months ended in Dec. 2025 was $1,241 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2025 was $2,405 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Sinopharm Group Co's annualized ROC % for the quarter that ended in Dec. 2025 was 6.83%. Sinopharm Group Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was 13.81%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Sinopharm Group Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was 14.53%.

Sinopharm Group Co  (OTCPK:SHTDF) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Sinopharm Group Co's annualized ROC % for the quarter that ended in Dec. 2025 is calculated as:

ROC % (Q: Dec. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2025 ) + Invested Capital (Q: Dec. 2025 ))/ count )
=2666.812 * ( 1 - 27.57% )/( (31853.284 + 24745.281)/ 2 )
=1931.5719316/28299.2825
=6.83 %

where

Invested Capital(Q: Jun. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=58538.301 - 21777.454 - ( 4907.563 - max(0, 38974.196 - 52252.453+4907.563))
=31853.284

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=55423.843 - 23750.424 - ( 6928.138 - max(0, 35030.324 - 49238.395+6928.138))
=24745.281

Note: The Operating Income data used here is two times the semi-annual (Dec. 2025) data.

2. Joel Greenblatt's definition of Return on Capital:

Sinopharm Group Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 is calculated as:

ROC (Joel Greenblatt) %(Q: Dec. 2025 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jun. 2025  Q: Dec. 2025
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=2482.668/( ( (2624.586 + max(16955.447, 0)) + (2308 + max(14074.82, 0)) )/ 2 )
=2482.668/( ( 19580.033 + 16382.82 )/ 2 )
=2482.668/17981.4265
=13.81 %

where Working Capital is:

Working Capital(Q: Jun. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(32775.278 + 9305.11 + 1660.366) - (21777.454 + 0 + 5007.853)
=16955.447

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(27631.334 + 8993.261 + 3277.368) - (23750.424 + 0 + 2076.719)
=14074.82

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Sinopharm Group Co's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Dec. 2025 )
=2405.163/16554.958
=14.53 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sinopharm Group Co EBIT Related Terms

Sinopharm Group Co EBIT Historical Data

* Premium members only.

The historical data trend for Sinopharm Group Co's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sinopharm Group Co EBIT Chart

Sinopharm Group Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3,259.38 3,167.68 3,146.79 2,298.53 2,427.83

Sinopharm Group Co Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,672.44 1,234.64 1,068.31 1,163.83 1,241.33

SHTDF vs MCK, COR, CAH: EBIT Comparison

For the Medical Distribution subindustry, Sinopharm Group Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sinopharm Group Co EV-to-EBIT vs Medical Distribution Industry

For the Medical Distribution industry and Healthcare sector, Sinopharm Group Co's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Sinopharm Group Co's EV-to-EBIT falls into.


SHTDF
78GF Score
Sinopharm Group Co Ltd SHTDF
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sinopharm Group Co EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $2,405 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of $2,405 Mil mean?
Sinopharm Group Co (SHTDF) has a EBIT of $2,405 Mil as of Dec. 2025. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Sinopharm Group Co.
Is Sinopharm Group Co's EBIT too high?
Sinopharm Group Co's current EBIT is $2,405 Mil. Overall, Sinopharm Group Co has a GF Score™ of 78/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sinopharm Group Co's EBIT compare to MCK and COR?
Sinopharm Group Co's EBIT of $2,405 Mil can be compared against companies in the Medical Distribution industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Medical Distribution company?
A good EBIT depends on the Medical Distribution industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Sinopharm Group Co. Sinopharm Group Co's current EBIT is $2,405 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sinopharm Group Co stock overvalued right now?
Based on GuruFocus' analysis, Sinopharm Group Co (SHTDF) is currently considered Modestly Undervalued. The stock's GF Value™ is $2.99, compared to a current price of $2.29 — trading 23.5% below its estimated fair value. The current EBIT is $2,405 Mil. Sinopharm Group Co's overall GF Score™ is 78/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Sinopharm Group Co (SHTDF), the current EBIT is $2,405 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sinopharm Group Co (SHTDF) Overvalued in 2026?

Based on GuruFocus' analysis, Sinopharm Group Co stock appears to be undervalued. The current stock price of $2.29 is trading 23.5% below its estimated GF Value™ of $2.99. GuruFocus considers Sinopharm Group Co to be Modestly Undervalued.

Key valuation signals for SHTDF:

  • EBIT: $2,405 Mil
  • GF Value™: $2.99 vs. price of $2.29 (23.5% below fair value)
  • GF Score™: 78/100 with 4 warning signs

No single metric tells the full story. See the SHTDF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Sinopharm Group Co Business Description

Address No. 385, East Longhua Road, Sinopharm Group Building, Huangpu District, Shanghai, CHN, 200023
Founded in 2003, Sinopharm is the largest wholesaler and retailer of drugs and medical devices in China and listed on the Hong Kong Stock Exchange in 2009. It is a core subsidiary of China National Pharmaceutical Group. Sinopharm's largest operating segment is pharmaceutical distribution, making up over 70% of its total revenue by the end of 2024. In 2018, Sinopharm acquired the largest Chinese medical device distributor, China National Scientific Instruments and Materials. Now, medical device distribution accounts for over 20% of Sinopharm's total revenue. Sinopharm's downstream customers range from hospitals and other health services institutions to end-customers.
78GF Score

Get the complete analysis for SHTDF

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.29
Price
$2.99
GF Value